Search
- Oct 18, 2023
Monte Rosa's CEO discusses yesterday's data for MRT-2359 in MYC-driven solid tumors
Markus Warmuth describes the PK/PD variables the company is seeing, how safety is shaping up, and a partnership with Roche.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A